Abstract: The invention concerns a sniff-on device engineered for collecting and measuring content of any gaseous sample, such as a breath or an air sample from a human or animal subject, or from an environment and determine with high accuracy at least one parameter relating to the sample content.

Abstract: The invention proposes an approach utilizing novel and artificially intelligent hybrid sensor arrays with multiplexed detection capabilities for disease-specific biomarkers from the exhaled breath of a subject. The technology provides a rapid and highly accurate diagnosis in various COVID-19 infection and transmission scenarios.

Abstract: A swallowable in-vivo device comprising a shell defining a cavity of the in-vivo device, the shell being formed with at least one aperture extending through the shell's wall. The in-vivo device is configured for allowing inlet of fluid into the cavity; The in in-vivo device further comprises and immunoassay system accommodated within the cavity and configured for interacting within the fluid; The in-vivo device also comprises at least one breach mechanism covering the at least one inlet for preventing ingress of fluids into the cavity via the inlet; The at least one breach mechanism comprises a film layer configured for reacting with the fluid and designed to be breached after a predetermined amount of exposure time to the GI fluid, corresponding to a desired location along the GI tract.

Abstract: A swallowable in-vivo device comprising a shell formed with at least one inlet extending across a shell wall and configured for allowing ingress of fluid at least into the shell; the shell accommodates therein a lateral flow (LF) arrangement configured for absorbing the fluid; the LF arrangement comprises a test zone configured for coming into contact, in-vivo, with a predetermined N substance present in the fluid or a compound comprising the substance, thereby causing a change in at least one property of the test zone; the shell further accommodates a sensor configured for sensing, in-vivo, the at least one property, at least when changed by interaction with the fluid; the LF arrangement has at least one curved segment, and at least one exposure portion juxtaposed with the inlet, configured for absorbing the fluid passing through the inlet into the shell.

Abstract: A swallowable in-vivo device comprising a shell formed with at least one inlet extending across a shell wall and configured for allowing ingress of fluid at least into the shell; the shell accommodates therein a lateral flow (LF) arrangement configured for absorbing the fluid; the LF arrangement comprises a test zone configured for coming into contact, in-vivo, with a predetermined N substance present in the fluid or a compound comprising the substance, thereby causing a change in at least one property of the test zone; the shell further accommodates a sensor configured for sensing, in-vivo, the at least one property, at least when changed by interaction with the fluid; the LF arrangement has at least one curved segment, and at least one exposure portion juxtaposed with the inlet, configured for absorbing the fluid passing through the inlet into the shell.

Abstract: Novel splice variants, amino acid sequences and nucleotide sequences thereof, and methods of using same.

Abstract: Novel splice variants, amino acid sequences and nucleotide sequences thereof, and methods of using same.

Abstract: Methods of tagging cancerous tissue for diagnostic applications, mainly for cancer screening purposes, include oral or luminal administrating of a tag molecule into a patient's gastrointestinal lumen either orally or through an enema, and tagging cancerous tissue present within the lumen with the tag molecule. The tag molecule may be a near infrared dye, e.g., IR783 or a derivative thereof, which showed to be of high concentration within cancerous tissue compared to normal tissue. The near infrared IR783 dye is administered, either orally or through an enema, as part of a pharmaceutical composition or formulation either as is or conjugated to a specific polymer. The formulation may comprise an enteric coating in order to keep the formulation intact prior to it reaching the target organ, which is to be tagged by the formulation.

Abstract: In-vivo methods and kits for detecting presence of a combination of biomarkers indicating colorectal cancer are described. One of the methods includes inserting into a patient a combination of binding agents comprising one binding agent having high affinity to CEACAM5 and at least one binding agent having high affinity to at least one of two biomarkers selected from Olfactomedin 4- (OLFM4) and S100P. The method further includes inserting into the patient an in-vivo sensing device, detecting an optical change using the in-vivo sensing device, which occurs when at least one of the combination of binding agents binds to at least one of the corresponding combination of biomarkers, and determining, based on the optical change, presence of colorectal cancer in the patient.

Abstract: Novel splice variants, amino acid sequences and nucleotide sequences thereof, and methods of using same.

Abstract: A device, system and method for detecting bile and blood are provided. The device may comprise a housing having a gap through which in-vivo fluids may flow, illumination sources on one side of the gap, a light detector which is facing the illumination sources and is positioned on the opposite side of the gap for detecting light which passes through the in-vivo fluids, and a transmitter to transmit the detected signals generated according to the detected light. The system may further comprise a receiver to receive the detected signals transmitted by the transmitter, and a processor. The method may comprise comparing the detected signals with a predetermined threshold calculated from the transmission spectra of bile and of blood and determining the presence and/or concentration of bile and blood in-vivo.

Abstract: Device, system and method for in-vivo detection of H. pylori. For example, an in-vivo device includes a housing, a reference electrode disposed on the housing, and a working electrode disposed on the housing in close proximity to the reference electrode. The working electrode is coated by litography or screen printing with salt such that substantially no current passes between the working electrode and the reference electrode. The in-vivo device further includes a measuring device for measuring current, impedance, and/or resistance between the working and the reference electrodes, and a transmitter for transmitting the measurements. Presence of ammonia, which is a byproduct of H. pylori, causes increase in current and thus decrease in impedance or resistance between the reference electrode and the working electrode; thereby measurements of current, impedance, and/or resistance indicate on presence or absence of H. pylori.

Abstract: In vivo devices, systems and methods for in vivo immunoassay include inserting into a patient's body lumen an in vivo diagnostic device comprising a housing. The housing of the device comprises a chamber, and a chromatography strip for immunoassay of a body lumen substance. The housing may further comprise a casing for the chromatography strip. The casing may comprise a first opening to allow entrance of in vivo liquids into the casing and a second opening into the chamber. The housing may further comprise a sensor to sense a property of the chromatography strip. Following insertion of the device into the patient's body, a sample is collected and the immunoassay is performed in vivo in areas of pathological lesions for a predetermined period of time. An in vivo image may be acquired or other data such as colorimetric or intensity data may be obtained from the chromatography strip.

Abstract: Devices, systems and methods for detecting in vivo pathology are provided. An in vivo sensing device comprises a reacting layer with at least one type of binding agent attached thereon, a sensor configured for sensing an optical change occurring on the reacting substrate, and at least one illumination source. In-vivo fluids are in constant contact with the reacting substrate so that in vivo marker indicating pathology may bind to the binding agent attached onto the reacting layer and may be viewed by the sensor.

Abstract: A device, system and method for detecting bile and blood are provided. The device may comprise a housing having a gap through which in-vivo fluids may flow, illumination sources on one side of the gap, a light detector which is facing the illumination sources and is positioned on the opposite side of the gap for detecting light which passes through the in-vivo fluids, and a transmitter to transmit the detected signals generated according to the detected light. The system may further comprise a receiver to receive the detected signals transmitted by the transmitter, and a processor. The method may comprise comparing the detected signals with a predetermined threshold calculated from the transmission spectra of bile and of blood and determining the presence and/or concentration of bile and blood in-vivo.

Abstract: Novel polypeptides and polynucleotides encoding same are provided. Also provided methods and pharmaceutical compositions which can be used to treat various disorders such as cancer, immunological-related, blood-related and skin-related disorders using the polypeptides and polynucleotides of the present invention. Also provided are methods and kits for diagnosing, determining predisposition and/or prognosis of various disorders using as diagnostic markers the novel polypeptides and polynucleotides of the present invention.

Abstract: Novel polypeptides and polynucleotides encoding same are provided. Also provided methods and pharmaceutical compositions which can be used to treat various disorders such as cancer, immunological-related, blood-related and skin-related disorders using the polypeptides and polynucleotides of the present invention. Also provided are methods and kits for diagnosing, determining predisposition and/or prognosis of various disorders using as diagnostic markers the novel polypeptides and polynucleotides of the present invention.

Abstract: Polypeptide sequences and polynucleotide sequences are provided. Also provided are annotative information concerning such sequences and uses for these sequences.

Abstract: Novel markers for ovarian cancer that are both sensitive and accurate. These markers are overexpressed and/or differentially expressed in ovarian cancer specifically, as opposed to normal ovarian tissue. The measurement of these markers, alone or in combination, in patient samples provides information that the diagnostician can correlate with a probable diagnosis, in ovarian cancer. The markers of the present invention, alone or in combination, show a high degree of differential detection between ovarian cancer and non-cancerous states.

Abstract: Novel splice variant nucleic acid sequences. The novel splice variants and their nucleic acid sequences according to the present invention may optionally be used for diagnosis of a variant-detectable disease as described herein.